Medical Updates: Testosterone Trends, Diabetes Drug Trials, and Hormone Therapy
Clinical insights on hormone use, diabetes management, and pharmaceutical industry developments.
1Rising Testosterone Prescriptions
Testosterone use among females has increased significantly since 2016. Data indicates these prescriptions are frequently issued without a documented diagnosis of hypoactive sexual desire disorder. This condition remains the sole evidence-based indication for such treatment, raising concerns among clinicians regarding the current prescribing patterns and the potential long-term health implications for patients.
2Diabetes Remission Predictors
Patients undergoing metabolic-bariatric surgery for type 2 diabetes face specific relapse risks. Research identifies longer baseline diabetes duration and a higher number of preoperative glucose-lowering medication classes as primary predictors of relapse. Understanding these variables is critical for clinicians to manage expectations and provide effective long-term follow-up care for post-surgical patients.
3Retatrutide Efficacy Comparison
Eli Lilly reported that its investigational triple agonist, retatrutide, demonstrated superior reductions in both HbA1c levels and body weight compared to semaglutide. This phase III head-to-head trial involved adults diagnosed with type 2 diabetes. These results highlight the evolving landscape of weight-loss and glucose-management therapies currently entering the competitive pharmaceutical market.
4Hormone Therapy Label Changes
The FDA has removed boxed warnings regarding cardiovascular disease, breast cancer, and dementia from prescribing information for several hormone therapy patches used for menopausal symptoms. Despite these regulatory updates, medical professionals warn that a small increase in breast cancer risk remains associated with certain hormonal therapies, necessitating careful patient monitoring and informed clinical decision-making.
5Medication-Induced Bone Loss
Various common medications are linked to decreased bone density, including oral corticosteroids, aromatase inhibitors, and androgen deprivation therapy. Anti-seizure medications and selective serotonin reuptake inhibitors also share this clinical association. Patients undergoing these long-term treatments require regular bone health assessments to mitigate the risk of fractures and maintain skeletal integrity over time.
6Strategic Pharmaceutical Partnerships
Eli Lilly has entered a partnership with the telehealth platform Hims Hers Health to increase access to its GLP-1 weight-loss drugs, specifically tirzepatide and orforglipron. This collaboration includes offering matched self-pay prices to consumers. Such initiatives reflect a broader industry shift toward utilizing digital health platforms to expand market reach for specialized medications.
7AstraZeneca Acquisition Interest
AstraZeneca has reportedly offered 10 billion dollars to acquire Rhythm Pharmaceuticals. The acquisition targets the company's first-in-class melanocortin-4 receptor agonist, setmelanotide, which is used for treating rare genetic obesities. This move underscores the high value placed on specialized therapies that address specific genetic markers in the growing field of metabolic health and obesity management.
8Clinical Policy Developments
Texas Children's Hospital has opened the nation's first detransition clinic, according to Attorney General Ken Paxton. Additionally, the Endocrine Society has established a new award honoring the late diabetes pioneer Jesse Roth, presenting the inaugural prize to C. Ronald Kahn. These developments reflect ongoing shifts in both clinical service delivery and academic recognition.